Kalaris Therapeutics (NASDAQ:KLRS) Rating Increased to Hold at Wall Street Zen

Kalaris Therapeutics (NASDAQ:KLRS) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Sunday.

A number of other equities research analysts have also recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kalaris Therapeutics in a report on Monday, December 29th. Citigroup reissued an “outperform” rating on shares of Kalaris Therapeutics in a report on Thursday, December 18th. Finally, Chardan Capital assumed coverage on Kalaris Therapeutics in a research report on Tuesday, December 23rd. They issued a “buy” rating and a $19.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Kalaris Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $14.00.

Kalaris Therapeutics Price Performance

Shares of KLRS opened at $8.67 on Friday. The firm has a 50 day simple moving average of $9.44 and a 200-day simple moving average of $7.18. Kalaris Therapeutics has a 1-year low of $2.14 and a 1-year high of $12.90. The stock has a market cap of $162.13 million, a price-to-earnings ratio of -2.30 and a beta of -0.13.

Insider Buying and Selling at Kalaris Therapeutics

In other news, Director Srinivas Akkaraju acquired 479,847 shares of Kalaris Therapeutics stock in a transaction that occurred on Thursday, December 18th. The shares were acquired at an average price of $10.42 per share, with a total value of $5,000,005.74. Following the completion of the purchase, the director owned 1,979,847 shares of the company’s stock, valued at approximately $20,630,005.74. This represents a 31.99% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 74.99% of the stock is currently owned by corporate insiders.

Institutional Trading of Kalaris Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. State Street Corp raised its holdings in Kalaris Therapeutics by 12.4% in the 4th quarter. State Street Corp now owns 25,410 shares of the company’s stock valued at $214,000 after acquiring an additional 2,800 shares during the last quarter. Nano Cap New Millennium Growth Fund L P acquired a new stake in shares of Kalaris Therapeutics during the fourth quarter worth $34,000. Barclays PLC purchased a new stake in shares of Kalaris Therapeutics in the fourth quarter valued at $51,000. Johnson Financial Group Inc. acquired a new position in Kalaris Therapeutics in the third quarter valued at $58,000. Finally, Keel Point LLC purchased a new position in Kalaris Therapeutics during the fourth quarter worth about $86,000. 66.05% of the stock is owned by hedge funds and other institutional investors.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.